Prions Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 01-07-2024
- Paid Up Capital ₹ 0.10 M
as on 01-07-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -84.99%
(FY 2020)
- Profit 4.34%
(FY 2020)
- Ebitda 1.70%
(FY 2020)
- Net Worth -1533.21%
(FY 2020)
- Total Assets 39.78%
(FY 2020)
About Prions Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Saurabh Singh, Shantanu Singh, and Rashmi Labh serve as directors at the Company.
- CIN/LLPIN
U52310PN2010PTC138132
- Company No.
138132
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Dec 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Prions Pharmaceuticals Private Limited offer?
Prions Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs.
Who are the key members and board of directors at Prions Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rashmi Labh  | Director | 01-Jan-2018 | Current |
| Saurabh Singh | Director | 29-Dec-2010 | Current |
| Shantanu Singh | Director | 29-Mar-2023 | Current |
Financial Performance of Prions Pharmaceuticals.
Prions Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 84.99% decrease. The company also saw a slight improvement in profitability, with a 4.34% increase in profit. The company's net worth observed a substantial decline by a decrease of 1533.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prions Pharmaceuticals?
In 2020, Prions Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Narayan Films Private LimitedActive 9 years 3 monthsSaurabh Singh, Shantanu Singh and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prions Pharmaceuticals?
Unlock and access historical data on people associated with Prions Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prions Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prions Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
